Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling

Bioorganic and Medicinal Chemistry

Volumn 19, Issue 1, 2011, Pages 504-512

  Lapinsky, David J ^a   Velagaleti, Ranganadh ^a   Yarravarapu, Nageswari ^a   Liu, Yi ^a   Huang, Yurong ^a   Surratt, Christopher K ^a   Lever, John R ^b,c   Foster, James D ^d   Acharya, Rejwi ^d   Vaughan, Roxanne A ^d   Deutsch, Howard M ^e  

^a DUQUESNE UNIVERSITY   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^e GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Attention deficit hyperactivity disorder; Cocaine; Concerta; Dopamine transporter; Methylphenidate; Photoaffinity labeling; Ritalin

Indexed keywords

1 (3 IODOPHENYLGLYOXYLYL)PIPERIDINE; 1 (3 IODOPHENYLGLYOXYLYL)PIPERIDINE 4 TOLUENESULFONYLHYDRAZONE; 1 (4 IODOPHENYLGLYOXYLYL)PIPERIDINE; 1 (4 IODOPHENYLGLYOXYLYL)PIPERIDINE 4 TOLUENESULFONYLHYDRAZONE; 2 N3 N BN 3 I METHYLPHENIDATE; 2 N3 N BN 4 I METHYLPHENIDATE; 3 I METHYLPHENIDATE; 3 N3 N BN 3 I METHYLPHENIDATE; 3 N3 N BN 4 I METHYLPHENIDATE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 4 I METHYLPHENIDATE; 4 N3 N BN 3 I METHYLPHENIDATE; 4 N3 N BN 4 I METHYLPHENIDATE; BENZYL DERIVATIVE; DOPAMINE TRANSPORTER; METHYLPHENIDATE; PIPERIDINE; THREO 3 IODOMETHYLPHENIDATE; THREO N (2 AZIDO BENZYL) 3 IODOMETHYLPHENIDATE; THREO N (2 AZIDO BENZYL) 4 IODOMETHYLPHENIDATE; THREO N (3 AZIDO BENZYL) 3 IODOMETHYLPHENIDATE; THREO N (3 AZIDO BENZYL) 4 IODOMETHYLPHENIDATE; THREO N (4 AZIDO BENZYL) 3 IODOMETHYLPHENIDATE; THREO N (4 AZIDO BENZYL) 4 (TRI N BUTYLSTANNYL)METHYLPHENIDATE; THREO N (4 AZIDO BENZYL) 4 IODOMETHYLPHENIDATE; THREO N (4 AZIDO BENZYL) 4 IODOMETHYLPHENIDATE I 125; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL MEMBRANE; CORPUS STRIATUM; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; INCUBATION TEMPERATURE; LIGAND BINDING; NONHUMAN; PHOTOAFFINITY LABELING; RADIOIODINATION; RAT;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DRUG DESIGN; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; METHYLPHENIDATE; PHOTOAFFINITY LABELS; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 78650753273     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2010.11.002     Document Type: Article

References (51)

1. R. Nair, and S.B. Moss Neuropsychiatr. Dis. Treat. 5 2009 421
2. For recent examples see: D.I. Kim, H.M. Deutsch, X. Ye, and M.M. Schweri J. Med. Chem. 50 2007 2718
3. M. Froimowitz, Y. Gu, L.A. Dakin, P.M. Nagafuji, C.J. Kelley, D. Parrish, J.R. Deschamps, and A. Janowsky J. Med. Chem. 50 2007 219
4. M.V. Solanto Behav. Brain Res. 94 1998 127
5. A.E. Fleckenstein, T.J. Volz, E.L. Riddle, J.W. Gibb, and G.R. Hanson Annu. Rev. Pharmacol. Toxicol. 47 2007 681
6. W.L. Woolverton, and K.M. Johnson Trends Pharmacol. Sci. 13 1992 193
7. T. Beuming, J. Kniazeff, M.L. Bergmann, L. Shi, L. Gracia, K. Raniszewska, A.H. Newman, J.A. Javitch, H. Weinstein, U. Gether, and C.J. Loland Nat. Neurosci. 11 2008 780
8. H. Bisgaard, M.A.B. Larsen, S. Mazier, T. Beuming, A.H. Newman, H. Weinstein, L. Shi, C.J. Loland, and U. Gether Neuropharmacology 60 2011 182
9. C.J. Loland, R.I. Desai, M.F. Zou, J. Cao, P. Grundt, K. Gerstbrein, H.H. Sitte, A.H. Newman, J.L. Katz, and U. Gether Mol. Pharmacol. 73 2008 813
10. S.P. Runyon, and F.I. Carroll Curr. Top. Med. Chem. 6 2006 1825
11. M.L. Trudell, S. Izenwasser, Dopamine Transporters: Chemistry, Biology, and Pharmacology 2008 Wiley Hoboken, NJ 123 304
12. M.E.A. Reith, J.L. Berfield, L. Wang, J.V. Ferrer, and J.A. Javitch J. Biol. Chem. 276 2001 29012
13. A.H. Newman, and S.S. Kulkarni Med. Res. Rev. 22 2002 1
14. O.T. Ukairo, C.D. Bondi, A.H. Newman, S.S. Kulkarni, A.P. Kozikowski, S. Pan, and C.K. Surratt J. Pharmacol. Exp. Ther. 314 2005 575
15. For naphthyl-containing phenylisothiocyanate tropane analogs see: V. Murthy, H.M.L. Davies, S.J. Hedley, and S.R. Childers Biochem. Pharmacol. 74 2007 336
16. V. Murthy, T.J. Martin, S. Kim, H.M.L. Davies, and S.R. Childers J. Pharmacol. Exp. Ther. 326 2008 587
17. For 3-iodo-4-azidococaine and characterization of its binding site within the sigma-1 receptor see: Y. Chen, A.R. Hajipour, M.K. Sievert, M. Arbabian, and A.E. Ruoho Biochemistry 46 2007 3532
18. 125I]-3-β-(4′-azido-3′-iodo-biphenyl-4- yl)-8-methyl-8-aza-bicyclo-[3.2.1]octane-2β-carboxylic acid methyl ester (JHC-2-48) see: A.H. Newman, J.H. Cha, J. Cao, T. Kopajtic, J.L. Katz, M.L. Parnas, R. Vaughan, and J.R. Lever J. Med. Chem. 49 2006 6621
19. 125I]iodo-4′-isothiocyanophenyl)butyl]- 2β-carbomethoxy-3β-(4-chlorophenyl)tropane (MFZ-3-37) see: J.R. Lever, M.F. Zou, M.L. Parnas, R.A. Duval, S.E. Wirtz, J.B. Justice, R.A. Vaughan, and A.H. Newman Bioconjugate Chem. 16 2005 644
20. For azido and isothiocyanate analogs of (S)-2β-substituted-3α- (bis[4-fluorophenyl]methoxy)tropanes and (R)-2β-substituted-3β-(3,4- dichlorophenyl)tropanes see: M.F. Zou, T. Kopajtic, J.L. Katz, and A.H. Newman J. Med. Chem. 46 2003 2908
21. For azido and isothiocyanate analogs of 3α-[bis(4′- fluorophenyl)methoxy]tropane see: M.F. Zou, T. Kopajtic, J.L. Katz, S. Wirtz, J.B. Justice, and A.H. Newman J. Med. Chem. 44 2001 4453
22. For an azido N-substituted 3α-[bis(4′-fluorophenyl)methoxy] tropane see: G.E. Agoston, R. Vaughan, J.R. Lever, S. Izenwasser, P.D. Terry, and A.H. Newman Bioorg. Med. Chem. Lett. 7 1997 3027
23. For azido and isothiocyanate substituted 3-carbamoylecgonine methyl ester analogs see: R.H. Kline, A.J. Eshleman, J. Wright, and M.E. Eldefrawi J. Med. Chem. 37 1994 2249
24. For irreversible ligands derived from (-)-cocaine or 3β- phenyltropan-2β-carboxylic acid methyl ester (WIN-35, 065-2) see: F.I. Carroll, Y. Gao, P. Abraham, A.H. Lewin, R. Lew, A. Patel, J.W. Boja, and M.J. Kuhar J. Med. Chem. 35 1992 1813
25. For a 4-[2-(diphenylmethoxy)ethyl]-1-benzyl piperidine based on GBR-12909 see: A.K. Dutta, X.S. Fei, R.A. Vaughan, J.D. Gaffaney, N.N. Wang, J.R. Lever, and M.E.A. Reith Life Sci. 68 2001 1839
26. For azido and isothiocyanato analogs of [3-(4-phenylalkylpiperazin-1-yl) propyl]bis(4-fluorophenyl)amines see: J. Cao, J.R. Lever, T. Kopajtic, J.L. Katz, A.T. Pham, M.L. Holmes, J.B. Justice, and A.H. Newman J. Med. Chem. 47 2004 6128
27. For isothiocyanate analogs of 9-[3-(cis-3,5-dimethyl-1-piperazinyl) propyl]-carbazole (Rimcazole) see: S.M. Husbands, S. Izenwasser, R.J. Loeloff, J.L. Katz, W.D. Bowen, B.J. Vilner, and A.H. Newman J. Med. Chem. 40 1997 4340
28. 3H]GBR-12935, see: S.P. Berger, R.E. Martenson, P. Laing, A. Thurkauf, B. Decosta, K.C. Rice, and S.M. Paul Mol. Pharmacol. 39 1991 429
29. 125I]iodophenyl]ethyl)piperazine (FAPP) see: F.R. Sallee, E.L. Fogel, E. Schwartz, S.M. Choi, D.P. Curran, and H.B. Niznik FEBS Lett. 256 1989 219
30. 125I-1-[2-(diphenylmethoxy)ethyl]-4-[2-(4-azido-3- iodophenyl)ethyl]piperazine (DEEP) see: D.E. Grigoriadis, A.A. Wilson, R. Lew, J.S. Sharkey, and M.J. Kuhar J. Neurosci. 9 1989 2664
31. For irreversible affinity labels based on aryl 1,4-dialkylpiperazines related to GBR-12783 see: H.M. Deutsch, M.M. Schweri, C.T. Culbertson, and L.H. Zalkow Eur. J. Pharmacol. 220 1992 173
32. 3H]-methylphenidate to rDAT see: M.M. Schweri, M.V. Thurkauf, M.V. Mattson, and K.C. Rice J. Pharmacol. Exp. Ther. 261 1992 936
33. For a photoaffinity ligand based on pyrovalerone, a structural variant of bupropion (Wellbutrin, Zyban), see: D.J. Lapinsky, S. Aggarwal, Y. Huang, C.K. Surratt, J.R. Lever, J.D. Foster, and R.A. Vaughan Bioorg. Med. Chem. 17 2009 3770
34. M. Indarte, J.D. Madura, and C.K. Surratt Proteins 70 2008 1033
35. R.A. Vaughan, M.L. Parnas, J.D. Gaffaney, M.J. Lowe, S. Wirtz, A. Pham, B. Reed, S.M. Dutta, K.K. Murray, and J.B. Justice J. Neurosci. Methods 143 2005 33
36. H.M. Deutsch, Q. Shi, E. Gruszecka-Kowalik, and M.M. Schweri J. Med. Chem. 39 1996 1201
37. M. Misra, Q. Shi, X. Ye, E. Gruszecka-Kowalik, W. Bo, Z. Liu, M.M. Schweri, H.M. Deutsch, and C.A. Venanzi Bioorg. Med. Chem. 18 2010 7221
38. D. Pan, S.J. Gatley, R. Chen, and Y.-S. Ding J. Labelled Compd. Radiopharm. 38 1996 523
39. J.M. Axten, L. Krim, H.F. Kung, and J.D. Winkler J. Org. Chem. 63 1998 9628
40. Gutman, A.; Zaltsman, I.; Shalimov, A.; Sotrihin, M.; Nisnevich, G.; Yudovich, L.; Fedotev, I. Patent US2004180928(A1).
41. D.O. Kiesewetter Tetrahedron: Asymmetry 4 1993 2183
42. D.L. Thai, M.T. Sapko, C.T. Reiter, D.E. Bierer, and J.M. Perel J. Med. Chem. 41 1998 591
43. R. Mornet, N.J. Leonard, J.B. Theiler, and M. Doree J. Chem. Soc., Perkin Trans. 1 5 1984 879
44. G. Dorman, and G.D. Prestwich Trends Biotechnol. 18 2000 64
45. M.L. Parnas, J.D. Gaffaney, M.F. Zou, J.R. Lever, A.H. Newman, and R.A. Vaughan Mol. Pharmacol. 73 2008 1141
46. R.A. Vaughan, D.S. Sakrikar, M.L. Parnas, S. Adkins, J.D. Foster, R.A. Duval, J.R. Lever, S.S. Kulkarni, and A.H. Newman J. Biol. Chem. 282 2007 8915
47. R.A. Vaughan, G.E. Agoston, J.R. Lever, and A.H. Newman J. Neurosci. 19 1999 630
48. R.A. Vaughan, and M.J. Kuhar J. Biol. Chem. 271 1996 21672
49. A. Shafi'ee, and G. Hite J. Med. Chem. 12 1969 266
50. W.C. Still, M. Kahn, and A. Mitra J. Org. Chem. 43 1978 2923
51. Y. Cheng, and W.H. Prusoff Biochem. Pharmacol. 22 1973 3099